Buy Rating Affirmed for Precision BioSciences as Milestones in Gene Editing Technology Loom

Analyst Soumit Roy of JonesTrading maintained a Buy rating on Precision BioSciences (DTIL – Research Report), retaining the price target of $30.00.

Soumit Roy has given his Buy rating due to a combination of factors related to Precision BioSciences’s advancements and potential in the gene editing sector. Roy anticipates that Precision will reach significant milestones in the next 12 to 24 months, which will validate their proprietary ARCUS genome editing technology. Key upcoming data releases, particularly from iECURE’s OTC-HOPE study and the PBGENE-HBV program, are expected to strengthen Precision’s position within the gene editing landscape. Roy’s confidence is further bolstered by the company’s solid financial footing, evidenced by their substantial cash reserves.
The optimism in Roy’s recommendation is also supported by Precision’s strategy to target chronic hepatitis B virus (cHBV), a condition affecting millions worldwide. With Precision’s pre-IND meeting with the FDA yielding positive feedback on trial design and assessments for PBGENE-HBV, Roy sees a clear path toward regulatory progress. The candidate has shown promising results in preclinical models, demonstrating high specificity and the potential to eliminate cccDNA without off-target editing. These developments, along with a strong pipeline of gene editing assets awaiting IND submissions, underpin Roy’s Buy rating for DTIL.

Roy covers the Healthcare sector, focusing on stocks such as Cassava Sciences, ESSA Pharma, and Anavex Life Sciences. According to TipRanks, Roy has an average return of -5.6% and a 27.33% success rate on recommended stocks.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Precision BioSciences (DTIL) Company Description:

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company’s propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.